Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botaretigene sparoparvovec - Johnson & Johnson Innovative Medicine/MeiraGTx

Next Previous
X
Search
Drug Profile

Botaretigene sparoparvovec - Johnson & Johnson Innovative Medicine/MeiraGTx

Alternative Names: A-004; AAV-RPGR - MeiraGTx; AAV2/5-hRKp.RPGR - MeiraGTx; AAV2/5-RPGR; AAV5-hRKp.RPGR; AAV5-RPGR; bota-vec; RPGR AAV gene therapy

Latest Information Update: 23 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University College London
  • Developer Johnson & Johnson Innovative Medicine; MeiraGTx
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference; RPGR protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Phase III Retinitis pigmentosa

Most Recent Events

  • 20 Dec 2023 Johnson & Johnson Innovative Medicine acquires botaretigene sparoparvovec from MeiraGTx
  • 20 Dec 2023 MeiraGTx terminates its license for Botaretigene sparoparvovec with Johnson & Johnson Innovative Medicine
  • 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top